Search Results | Blood | American Society of Hematology

1-20 of 1830

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

DOI: https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Blood (2019) 134 (Supplement_1): 2426.

DOI: https://doi.org/10.1182/blood-2019-129820

Published: 2019

Journal Articles

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, MD, Qian Jiang, MD

Blood (2019) 134 (Supplement_1): 2940.

DOI: https://doi.org/10.1182/blood-2019-130081

Published: 2019

Journal Articles

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Binod Dhakal, MBBS, Muhammad Umair Mushtaq, MD, Ashley Cunningham, MD, Athanasios Papadas, MD, Adam Pagenkopf, BS, Joshua Wiesner, Catherine Leith, MBBChir, Peiman Hematti, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD, Fotis Asimakopoulos, PhDMBBChir,

Blood (2019) 134 (Supplement_1): 3088.

DOI: https://doi.org/10.1182/blood-2019-127565

Published: 2019

Journal Articles

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Rami S. Komrokji, MD, David A Sallman, MD, Najla Al Ali, M.Sc, Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Eric Padron, MD, Alan F. List, MD

Blood (2019) 134 (Supplement_1): 3001.

DOI: https://doi.org/10.1182/blood-2019-127462

Published: 2019

Journal Articles

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Timothy J Voorhees, MD, Natalie S Grover, MD, Jonathan Galeotti, MD MS, Nathan D Montgomery, MD, Dominic T. Moore, MPH, MS, Anne Beaven, MD, Christopher Dittus, DO

Blood (2019) 134 (Supplement_1): 2915.

DOI: https://doi.org/10.1182/blood-2019-126228

Published: 2019

Journal Articles

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Gloria G Chan, MS, Jiaji G Chen, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2823.

DOI: https://doi.org/10.1182/blood-2019-125069

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Lindsey E. Roeker, MD, Jennifer R. Brown, MD PhD, Peter Dreger, Oscar B Lahoud, MD, Toby A. Eyre, MBBChir, MRCP, Danielle M. Brander, MD, Alan Skarbnik, MD, Catherine C. Coombs, MD, Haesook T. Kim, PhD, Steven T Manchini, BS, Timothy J Voorhees, MD, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Harriet S Walter, Arvind K. Arumainathan, FRCPath, MBBS, MRCP,, Andrea Sitlinger, MD, Craig S. Sauter, MD, Sergio A Giralt, MD, Miguel-Angel Perales, MD, Anthony R. Mato, MDMSCE

Blood (2019) 134 (Supplement_1): 3321.

DOI: https://doi.org/10.1182/blood-2019-124140

Published: 2019

Journal Articles

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

Nikhita Gadi, MDMSc, Linda Schmidt, RN, Jaeil Ahn, PhD, Tianmin Wu, MS, Scott D. Rowley, MD, Elli Gourna Paleoudis, PhD, Michele L. Donato, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 3141.

DOI: https://doi.org/10.1182/blood-2019-129504

Published: 2019

Journal Articles

Depletion of Pre-Transplant Skeletal Muscle Is a Significant Poor Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation

Yasuhiko Shibasaki, MD, Kenta Kobayashi, Tatsuya Suwabe, MD, Kyoko Fuse, MD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD

Blood (2019) 134 (Supplement_1): 3322.

DOI: https://doi.org/10.1182/blood-2019-124733

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

DOI: https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

DOI: https://doi.org/10.1182/blood-2019-126211

Published: 2019

Journal Articles

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Henry Wood, MBBS, Katy Sanchez, BSc, MSc, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Austin Kulasekararaj, MD MRCP, FRCPath, Hugues de Lavallade, MD PhD, Deborah Yallop, MBBS, FRCP, FRCPath, PhD, Shireen Kassam, MBBS, FRCPath, PhD, Robin M. Ireland, MBBS, FRCP, FRCPath, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Alan Dunlop, BSc, MSc

Blood (2019) 134 (Supplement_1): 4566.

DOI: https://doi.org/10.1182/blood-2019-131711

Published: 2019

Journal Articles

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

James Croft, MBBS, BSc, Andrew Hall, Amy L Sherborne, PhD, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Louise Flanagan, PhD, Mamta Garg, MD FRCP, FRCPath, Suzana Couto, Maria Wang, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, William E Pierceall, PhD, Anjan Thakurta, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 4327.

DOI: https://doi.org/10.1182/blood-2019-123640

Published: 2019

Journal Articles

Decitabine As First Line Treatment in Acute Myeloid Leukemia of the Elderly: Real-Life Experience from a Single Center

Eleni Bouronikou, Eleni Georgiadi, George Vassilopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5137.

DOI: https://doi.org/10.1182/blood-2019-123028

Published: 2019

Journal Articles

High Pre-Transplant Free Interleukin-18 Is Associated with Poor Hematopoietic Recovery after Allogeneic Stem Cell Transplantation

Lambros Kordelas, MD, Aleksandar Radujkovic, MD, Hao Dai, Rashit Bogdanov, PhD, Dietrich W. Beelen, Carsten Müller-Tidow, MD, Peter Dreger, Thomas Luft, MD PhD

Blood (2019) 134 (Supplement_1): 4507.

DOI: https://doi.org/10.1182/blood-2019-124278

Published: 2019

Journal Articles

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3836.

DOI: https://doi.org/10.1182/blood-2019-128853

Published: 2019

Journal Articles

Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

Blood (2019) 134 (Supplement_1): 2755.

DOI: https://doi.org/10.1182/blood-2019-122311

Published: 2019

Journal Articles

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Feng Zhu, Yongxian Hu, MD, Wei Guoqing, He Huang, Wenjun Wu, MD

Blood (2019) 134 (Supplement_1): 3220.

DOI: https://doi.org/10.1182/blood-2019-129649

Published: 2019

Journal Articles

Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival

Dipenkumar Modi, MD, Seongho Kim, PhD, Jie Chi, MD, Lois Ayash, MD, Asif Alavi, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 3311.

DOI: https://doi.org/10.1182/blood-2019-124838

Published: 2019

2 3 4 5

NARROW

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

Depletion of Pre-Transplant Skeletal Muscle Is a Significant Poor Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

Decitabine As First Line Treatment in Acute Myeloid Leukemia of the Elderly: Real-Life Experience from a Single Center

High Pre-Transplant Free Interleukin-18 Is Associated with Poor Hematopoietic Recovery after Allogeneic Stem Cell Transplantation

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only